The efficacy of pharmaceutical aerosols relates to its deposition in the clinically relevant
regions of the lungs, which can be assessed by in vivo lung deposition studies. Dry powder …

Abstract Development of a new drug for the treatment of lung disease is a complex and time
consuming process involving numerous disciplines of basic and applied sciences. During …

The pharmaceutical industry is currently facing multiple challenges, in particular the low
number of new drug approvals in spite of the high level of R&D investment. In order to …

In this Series paper, we review the current evidence for the use of high-flow oxygen therapy,
inhaled gases, and aerosols in the care of critically ill patients. The available evidence …

Accurate knowledge of the delivery of locally acting drug products, such as metered-dose
inhaler (MDI) formulations, to large and small airways is essential to develop reliable in …

Exposure of lung airways to detrimental suspended aerosols in the environment increases
the vulnerability of the respiratory and cardiovascular systems. In addition, recent …

Background Asthma is a disease characterized by ventilation heterogeneity (VH). A number
of studies have demonstrated that VH markers derived by using impulse oscillometry (IOS) …

Introduction: The effectiveness of drug delivery to the lungs is inextricably linked to the
fundamental interactions that occur between particles and flow in the extrathoracic airway …

Background Despite the promise of respiratory simulations improving diagnosis and
treatment of pulmonary diseases, model predictions have yet to be translated into the clinical …

The deposition of aerosol particles, eg, fine dust particles, diesel aerosols, or wood dust, in
the human lung is responsible for many respiratory diseases. Small respirable particles can …